Oculis (NASDAQ:OCS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Oculis (NASDAQ:OCS) had its target price increased by analysts at Stifel Nicolaus from $35.00 to $40.00 in a report released on Friday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price target points to a potential upside of 88.24% from the stock’s previous close.

Several other research firms have also weighed in on OCS. Lifesci Capital began coverage on shares of Oculis in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price objective on the stock. Bank of America cut their price target on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. JPMorgan Chase & Co. assumed coverage on shares of Oculis in a research report on Friday. They set an “overweight” rating and a $38.00 price objective for the company. Chardan Capital reissued a “buy” rating and issued a $51.00 target price on shares of Oculis in a research report on Tuesday, November 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price target on shares of Oculis in a research report on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $41.50.

Oculis Stock Up 9.1%

Shares of NASDAQ OCS opened at $21.25 on Friday. Oculis has a 1 year low of $14.00 and a 1 year high of $23.08. The firm’s 50-day moving average is $20.10 and its 200-day moving average is $18.86. The company has a current ratio of 4.47, a quick ratio of 4.47 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $1.11 billion, a PE ratio of -8.43 and a beta of 0.32.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.10. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. Equities analysts expect that Oculis will post -2.09 EPS for the current year.

Institutional Trading of Oculis

A number of hedge funds have recently modified their holdings of the stock. Bosun Asset Management LLC bought a new position in Oculis during the 2nd quarter worth $378,000. Marshall Wace LLP acquired a new position in Oculis in the second quarter valued at about $393,000. Geode Capital Management LLC lifted its position in Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after purchasing an additional 6,384 shares during the period. Bank of America Corp DE grew its stake in Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after buying an additional 878 shares in the last quarter. Finally, Woodline Partners LP grew its stake in Oculis by 65.8% during the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after buying an additional 33,265 shares in the last quarter. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.